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complex promotes PARP inhibitor
resistance in BRCA1-deficient cells.
Mechanistically, the CST complex
maintains double-strand break end
stability in addition to its role in protecting
telomeric ends.
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Selective elimination of BRCA1-deficient cells by in-
hibitors of poly(ADP-ribose) polymerase (PARP) is a
prime example of the concept of synthetic lethality
in cancer therapy. This interaction is counteracted
by the restoration of BRCA1-independent homolo-
gous recombination through loss of factors such as
53BP1, RIF1, and REV7/MAD2L2, which inhibit end
resection of DNA double-strand breaks (DSBs). To
identify additional factors involved in this process,
we performed CRISPR/SpCas9-based loss-of-func-
tion screens and selected for factors that confer
PARP inhibitor (PARPi) resistance in BRCA1-defi-
cient cells. Loss of members of the CTC1-STN1-
TEN1 (CST) complex were found to cause PARPi
resistance in BRCA1-deficient cells in vitro and
in vivo. We show that CTC1 depletion results in the
restoration of end resection and that the CST com-
plex may act downstream of 53BP1/RIF1. These
data suggest that, in addition to its role in protecting
telomeres, the CST complex also contributes to pro-
tecting DSBs from end resection.
INTRODUCTION
The synthetic lethal interaction between BRCA1 deficiency and
poly(ADP-ribose) polymerase (PARP) inhibition is a well-estab-
lished therapeutic paradigm with encouraging response rates in
the clinic (Lord and Ashworth, 2017). This has resulted in theCell
This is an open access article under the CC BY-Nrecent regulatory approval of three PARP inhibitors (PARPis) for
the treatment of serous ovarian cancers and one PARPi, olaparib,
for the treatment of BRCA-mutated, HER2-negative breast can-
cers. Moreover, the BRCA-PARP paradigm might be extended
beyond breast andovarian cancer because recent clinical studies
indicate that a subset of prostate cancers harbor a homologous
recombination (HR) defect and, hence, might benefit from ola-
parib treatment (Mateo et al., 2015; Pritchard et al., 2016).
Despite this success, long-lasting clinical response rates in pa-
tients with advanced disease are limited by the development of
resistance, the mechanisms of which have not been fully eluci-
dated. A major class of resistance mechanisms centers on re-
expression of functional BRCA1 or BRCA2 protein, either through
promoterdemethylation,genetic reversion, orgene fusions (Patch
et al., 2015; Swisher et al., 2008; Ter Brugge et al., 2016). How-
ever, our previous work also identified the existence of additional
BRCA1-independent resistance mechanisms in the K14cre;
Brca1F/F;p53F/F (KB1P) genetically engineered mouse model of
hereditarybreast cancer (Liuet al., 2007). In thismodel, re-expres-
sion of functional BRCA1 is excluded because of the large, engi-
neered, intragenic Brca1 deletion, which spans multiple exons.
Despite the absence of functional BRCA1 restoration, KB1P tu-
mors acquired resistance to PARPi treatment. In addition to acti-
vation of the P-glycoprotein drug efflux transporter (Rottenberg
et al., 2008), the BRCA1-independent resistance mechanisms
in KB1P tumors predominantly involved the partial restoration
of HR activity through re-wiring of the DNA damage response
(DDR); for example, by loss of 53BP1 (Bouwmanet al., 2010; Bun-
ting et al., 2010; Jaspers et al., 2013). These seminal findings
have spurred a number of studies inwhich additional downstream
antagonists of end resection were identified, including RIF1
(Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Dı´azReports 23, 2107–2118, May 15, 2018 ª 2018 The Author(s). 2107
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
et al., 2013; Zimmermann et al., 2013) and REV7/MAD2L2
(Boersma et al., 2015; Xu et al., 2015). However, the currently
known resistance factors cannot explain all PARPi-resistant
cases, suggesting that additional proteins functioning in this
pathway remain to be identified. Moreover, although the loss
of resection antagonists partially restores end resection of DNA
double-strand breaks (DSBs), none of these factors have direct
functions in DNA metabolism, raising the question of how DNA
metabolism at DSBs might be altered to stimulate end resection.
The function of the 53BP1 pathway is not exclusive to canon-
ical DSB repair, but it also acts on telomeres (Panier and Boulton,
2014). Because telomere ends resemble DSBs located at chro-
mosomal termini, cells have evolved several mechanisms to pro-
tect telomeres from DSB end processing and chromosome end-
to-end fusions (Sfeir and de Lange, 2012). Mammalian telomeres
consist of TTTAGG repeats ending with a single-strand G-rich
overhang. The single-stranded DNA (ssDNA) overhang is crucial
in telomere maintenance because it is required for the formation
of the T-loop structure (Makarov et al., 1997; McElligott and
Wellinger, 1997). Notably, excessive resection of telomere
ends is inhibited by the action of the shelterin complex and by
the 53BP1 pathway (Lazzerini-Denchi and Sfeir, 2016; Sfeir
and de Lange, 2012).
Besides the mechanisms that have evolved to protect telo-
meric overhangs from excessive processing, it has recently
been shown that the RPA-like CTC1-STN1-TEN1 (CST) complex
is able to localize to telomeric ssDNA and mediate a fill-in reac-
tion executed by polymerase-alpha (POLA) to buffer resection
activity (Feng et al., 2017; Miyake et al., 2009; Wu et al., 2012).
Notably, it was demonstrated that the binding of the CST com-
plex to ssDNA is not particularly sequence-specific, although a
partial preference for G-rich regions has been described (Hom
and Wuttke, 2017; Miyake et al., 2009). Additionally, CST com-
ponents do not localize exclusively to telomeres (Miyake et al.,
2009). This might argue that the CST complex also has non-telo-
meric functions.
In this study, three independent forward genetic CRISPR/
SpCas9-based loss-of-function screening approaches were em-
ployed to identify factors that induce PARPi resistance in BRCA1-
deficient cells. Together, these screens identified that defects in
Ctc1, or its CST complex members Stn1 or Ten1, suppress the
synthetic lethal interaction between BRCA1 and PARP inhibition.
Inactivation of CTC1 is sufficient to drive PARPi resistance in vivo.
Depletion of CTC1 increased end resection activity and subse-
quently restored RAD51 focus formation upon ionizing radiation
(IR)-induced DNA damage, providing a mechanistic basis for
these observations. Moreover, the CST complex facilitates
canonical non-homologous end joining (c-NHEJ)-driven repair.
Together, these data demonstrate that the CST complex plays a
moreglobal role inDNArepairbeyond theprotectionof telomeres.
RESULTS
Forward Genetic CRISPR/SpCas9 Screens Identify
Selective Enrichment for Loss of CTC1 during PARPi
Treatment in BRCA1-Deficient Cells
To identify factors that modulate the synthetic lethal interaction
between BRCA1 and PARP, we carried out three independent2108 Cell Reports 23, 2107–2118, May 15, 2018forward genetic loss-of-function CRISPR/SpCas9 screens (Fig-
ure 1). All screens were analyzed by harvesting cells before
and after PARPi treatment, after which single guide RNA (sgRNA)
sequences were amplified from genomic DNA by PCR and
analyzed by next-generation sequencing. The screening data
were processed by the model-based analysis of genome-wide
CRISPR-Cas9 knockout (MAGeCK) or the drugZ algorithm
(Li et al., 2014; Wang et al., 2017), and the results were sorted
on positive selected gene ranks to allow comparison across
screens. Additional experimental details are provided in the Sup-
plemental Experimental Procedures.
The first PARPi resistance screen was performed in SpCas9-
expressing KB1P-G3 mouse mammary tumor cells (Jaspers
et al., 2013) using a custom-made lentiviral sgRNA library target-
ing 1,752 DDR-related genes (Table S1) cloned into the doxycy-
cline-inducible pLenti-sgRNA-tetR-T2A-PuroR vector (Prahallad
et al., 2015). The screen was performed at 1003 coverage, and
cells were selected with two different PARPis, olaparib and
AZD2461 (Oplustil O’Connor et al., 2016), at the approximate
inhibitory concentration 90 (IC90) for 14 days (Figure 1A).
Although sgRNAs targeting Tp53bp1 were deliberately removed
from the library to avoid the possibility that this potent PARPi
resistance factor might obscure the effects of other genes, its
upstream regulatory factor Rnf8 scored among the top genes
(Figure 1B).
The second PARPi resistance screen was performed in
SpCas9-expressing Brca1/;Trp53/ mouse embryonic stem
cells (mESCs) infected with a genome-wide lentiviral sgRNA
library targeting 19,150 genes (Koike-Yusa et al., 2014). The
screen was performed at 753 coverage in two independent
transductions, and cells were selectedwith olaparib at a concen-
tration of 15 nM for 10 days. As expected, Tp53bp1 and Rnf8
scored among the top genes and ranked #1 and #15, respec-
tively (Figure 1C).
A third PARPi resistance screen was performed in
BRCA12288delT mutant SUM149PT human breast cancer cells
(Elstrodt et al., 2006). SUM149PT cells expressing doxycy-
cline-inducible SpCas9 were lentivirally infected with a
genome-wide sgRNA library targeting 18,010 genes (Tzelepis
et al., 2016). This screen was performed at 1,0003 coverage,
and cells were selected in the presence of doxycycline plus
100 nM talazoparib for 2 weeks. The screen was dominated
by sgRNAs targeting PARP1, the drug target of talazoparib.
Although PARP1 loss is expected to be lethal in BRCA1-deficient
cells, the selection for PARP1 loss in SUM149PT cells might be
attributed to residual BRCA1 activity, which might enable cell
survival in the absence of PARP1 (Pettitt et al., 2017; Wang
et al., 2016). Moreover, TP53BP1 scored among the top en-
riched genes and ranked #7 (Figure 1D).
The results from these three independent screens were
collated to identify consistent outliers. The top 20 genes were
selected from the DDR-focused library screen in KB1P-G3 cells.
Because the genome-wide libraries contain about 10-fold more
genes than the DDR-focused library, the top 200 genes were
selected from the mESC and SUM149PT screens, and these
were plotted in a Venn diagram (Figure 1E). Notably, Ctc1 was
the only gene that consistently scored in all three screens
(ranked #10, #39, and #39 in the KB1P-G3, mESC, and
Figure 1. Multiple Independent CRISPR/SpCas9 Loss-of-Function Screens Identify CTC1 as a Driver of PARPi Resistance in BRCA1-Defi-
cient Cells
(A) Schematic overview of the screening approach utilized across the different screens. Each screen was performed on a different cell line and screened with a
different library, which is indicated per screen.
(B) SpCas9-expressing KB1P-G3 cells were screened with a DNA damage response (DDR)-focused library at 1003 coverage. Cells were plated for clonogenic
growth in the presence of olaparib (75 nM) or AZD2461 (250 nM) for 14 days, and sgRNA abundance in treated populations was compared with the starting
population using MAGeCK software. Gene-based p values were log-transformed and plotted based on the positive rank (enrichment). Each dot represents a
unique gene.
(C)Brca1/;Trp53/mouse embryonic stem cells (mESCs) were screenedwith a genome-wide library in two independent transductions at 753 coverage. After
10 days of culture in the presence of olaparib (15 nM), treated populations were compared with the untreated population using MAGeCK software. Gene based
p values were log-transformed and plotted based on the positive rank (enrichment). Each dot represents a unique gene.
(D) A derivative of theBRCA1mutant SUM149PT human triple-negative breast tumor cell line carrying a doxycycline-inducible SpCas9 expression construct was
lentivirally infected with a genome-wide guide RNA library at more than 1,0003 coverage. Cells were cultured in the presence of doxycycline plus 100 nM ta-
lazoparib for 2 weeks. The sgRNA abundance in treated populations was compared with the starting population using drugZ. Gene-based Z scores were log-
transformed and plotted based on the positive z-rank (enrichment). Each dot represents an individual gene.
(E) The top 20 genes in the KB1P-G3 screen and the top 200 genes in the mESC and SUM149PT screens were selected and plotted in a Venn diagram to identify
consistent outliers.SUM149PT screens, respectively). Moreover, Stn1 (also known
as Obfc1) scored in two of three screens. These results caught
our attention because both CTC1 and STN1 are members of
the CST complex. Although the CST complex has known func-
tions in telomere metabolism, these PARPi resistance screens
might point toward non-telomeric functions of the CST complex.
Because Ctc1 was a top hit in all three independent screens in
both mouse and human cells, we prioritized this gene for further
validation.
Depletion of CTC1 Suppresses the Synthetic Lethal
Interaction between BRCA1 Deficiency and PARP
Inhibition
To validate the effect of CTC1 on PARPi sensitivity in BRCA1-
deficient cells, we transfected KB1P-G3 cells with pX330 vectors
containing three sgRNAs targeting a putative oligonucleotide-
binding (OB) fold domain of Ctc1 (Figure 2A). The polyclonal tar-geted populations were efficiently modified for the target site
(Figures 2B–2D), as shown by TIDE (tracking of insertions or de-
letions [indels] by decomposition) analysis (Brinkman et al.,
2014). These populations were subsequently treated with ola-
parib (75 nM) or AZD2461 (250 nM), the same concentrations
as used for the screen. As expected, parental KB1P-G3 cells
or KB1P-G3 cells targeted by a non-targeting sgRNA (sgNT)
showed high sensitivity to PARPi treatment. In contrast, Ctc1-
targeted cells showed resistance to treatment, indicating that
depletion of CTC1 suppresses the synthetic lethal interaction be-
tween BRCA1 deficiency and PARP inhibition (Figures 2E and F).
This could not be attributed to an effect on cell proliferation
because we observed no difference in the doubling time upon
depletion of CTC1 (Figure 2G).
We next investigated whether Ctc1-mutated cells would be
specifically selected out from a mixed population by prolonged
PARPi treatment. A competition assay was performed in whichCell Reports 23, 2107–2118, May 15, 2018 2109
Figure 2. Depletion of CTC1 Suppresses the Synthetic Lethal Interaction between BRCA1 Deficiency and PARP Inhibition
(A) Schematic overview of the Ctc1 gene, in which putative OB fold domains and sgRNA target locations are indicated (adapted from Miyake et al., 2009).
(B–D) KB1P-G3 cells were transfected with pX330puro vectors containing the indicated sgRNAs, and the target region was PCR-amplified to verify allele
modification using TIDE software.
(E) The indicated Ctc1-mutated KB1P-G3 cell lines were plated for clonogenic growth upon olaparib (75 nM) or AZD2461 (250 nM) treatment. Three independent
experiments were performed, and each condition was plated in triplicate. One representative well per condition is shown for each independent experiment.
(F) Quantification of crystal violet staining in (E). Data were plotted relative to the growth of untreated sgNT cells and are presented as mean ± SD (n = 3 inde-
pendent experiments). Significance was calculated by two-way ANOVA with Dunnett’s multiple comparisons test (****adjusted p = 0.0001).
(G) Relative cell proliferation was determined by IncuCyte Zoom Live – Cell Analysis System measurements. Each data point represents the average of three
independent experiments, and in each experiment, six replicate wells were measured and averaged. Data represent mean ± SD (n = 3). Doubling times
(exponential growth equation) were calculated using GraphPad software, and significance was calculated by one-way ANOVA with Dunnett’s multiple com-
parisons test.
(H and I) SpCas9-expressing KB1P-G3 cells were transduced with doxycycline-inducible pLenti-sgRNA-tetR-T2A-PuroR vectors containing the indicated
sgRNAs. Polyclonal populations were plated for clonogenic growth with or without AZD2461 (250 nM) (H). Cells were passaged every 10 days for a total of three
times. At the endpoint, wells were fixed and stained with crystal violet, and allele distributions were determined from each condition using TIDE software (I).
(J) KB1P-G3 cells were transfected with pX330puro vectors containing sgRNAs targeting Stn1 and Ten1 and cultured in the presence or absence of 75 nM
olaparib as in (E). Data were analyzed as in (F) and reflect at least two independent experiments.
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Figure 3. Loss of CST Complex Members Induces PARPi Resistance in BRCA1-Deficient mESCs and SUM149PT Breast Cancer Cells
(A) Ctc1, Stn1, and Ten1 were targeted in R26CreERT2;Brca1SCo/D mESCs using pLentiCRISPRv2 vectors. Following transduction and selection, the Brca1-Sco
allele was recombined by activation of CreERT2 via addition of 4-OHT, after which cells were plated out for clonogenic growth. Cells were fixed and stained with
crystal violet.
(B) Brca1 alleles from surviving populations were PCR-amplified using specific primers to detect Brca1Sco (Sco) and recombined Brca1DSco (DelSco) alleles.
(C) BRCA1-mutant SUM149PT cells were transfected with the EditR CRISPR system, and the indicated CRISPR RNA (crRNA) and then continuously cultured in
the presence of 50 nM talazoparib over a 14-day period, at which point cell viability was estimated by use of CellTiter-GLo reagent. Median effects from three
independent experiments are shown. Error bars represent SEM. *p = 0.0415 and 0.0201, respectively; **p = 0.0013 and 0.0011, respectively; ****p = < 0.0001;
unpaired two-tailed Student’s t test.the evolution of polyclonal populations was monitored by
the TIDE algorithm to quantify changes in allele distributions.
sgRNAs were cloned in the pLenti-sgRNA-tetR-T2A-Puro vector
and introduced in SpCas9-expressing KB1P-G3 cells by lentivi-
ral transduction. The population was mutagenized by doxycy-
cline-induced expression of the sgRNA for 5 days, after which
cells were plated without doxycycline for clonogenic growth. Af-
ter 10 days of culture in the presence or absence of AZD2461,
the cells were harvested and re-plated at equal amounts every
10 days for an additional two rounds, resulting in a total treat-
ment duration of 30 days. Although non-transduced cells or cells
transduced with a non-targeting sgRNA were effectively killed
by this prolonged treatment, Ctc1-targeted cells survived (Fig-
ure 2H). This coincided with an enrichment of Ctc1 frameshift
mutations compared with untreated populations, which were
kept in culture for the same duration (Figure 2I).
To study whether this effect is CTC1-specific or a feature of
the CST complex, we genetically inactivated the other two CST
complex members Stn1 and Ten1, and treated these cells with
olaparib under the same conditions as used for Ctc1. CRISPR/
SpCas9-mediated disruption of Stn1 or Ten1 also induced
PARPi resistance, recapitulating the effect of Ctc1 (Figure 2J).
This is consistent with the identification of STN1 in the PARPi
resistance screens (Figure 1E) and shows that PARPi sensitivity
is modulated by all CST complex members rather than CTC1
alone.
These data were corroborated inBrca1/;Trp53/mESCs in
which CRISPR/SpCas9-assisted inactivation of Ctc1 increased
survival upon olaparib treatment, which was accompanied bya selection for frameshifting alleles (Figures S1A and S1B).
Furthermore, we targeted the CST complex members in
R26CreERT2;Brca1SCo/DmESCs, which harbor a selectable condi-
tional Brca1Sco allele that can be inactivated byCreERT2 through
the addition of 4-hydroxytamoxifen (4-OHT) (Bouwman et al.,
2010). Although 4-OHT-induced inactivation of BRCA1 caused
lethality in untransduced R26CreERT2;Brca1SCo/D mESCs, clonal
outgrowth was observed for cells depleted of CTC1, STN1,
or TEN1 (Figure 3A). Complete switching of the conditional
Brca1Sco allele in the surviving population was confirmed by
PCR, ruling out that clonal outgrowth was due to a non-recom-
bined Brca1Sco allele (Figure 3B). Finally, depletion of CTC1 in
SUM149PT cells enhanced cell survival in the presence of tala-
zoparib, as did depletion of 53BP1 (Figure 3C), confirming that
this effect was not restricted to mouse cells.
In summary, we confirmed that the CST complex promotes
PARPi-induced cell lethality in BRCA1-deficient cells. We there-
fore looked at the role of the CST complex in preventing global
DNA damage, focusing on CTC1.
CTC1 Antagonizes End Resection at Non-Telomeric
DSBs
During the repair of DSBs, a critical decision is made between
initiating repair via NHEJ or via HR, which both require distinct
end processing. This decision is tightly balanced by end protec-
tion factors, such as 53BP1 or RIF1, which antagonize resection
to direct repair via NHEJ, and BRCA1, which promotes end
resection to direct repair via HR (Chapman et al., 2013; Daley
and Sung, 2014; Escribano-Dı´az et al., 2013; Feng et al., 2015;Cell Reports 23, 2107–2118, May 15, 2018 2111
Figure 4. CTC1 Functions as a Resection Antagonist on Non-telomeric DSBs
(A and B) CTC1 depletion induces RPA-coated ssDNA overhangs at sites of DNA damage in BRCA1-defient KB1P cells.
(A) Representative images of RPA-negative and RPA-positive 53BP1-labeled alpha tracks in the indicated CRISPR/SpCas9-targeted KB1P-G3 cells (highlighted
by the white arrowheads). Scale bars represent 5 mm.
(B) RPA co-localization was quantified 1 hr after irradiation with an Americium-241 (241Am) point source. The experiment was performed three times, and in each
independent experiment, aminimumof 100 trackswere analyzed. Data are plotted asmean ±SEM. Significance was calculated by unpaired two-tailed Student’s
t test (**p < 0.01).
(C and G) CTC1 depletion restores formation of DNA damage-induced RAD51 foci in BRCA1-deficient cells.
(C) Representative confocal images of CRISPR/SpCas9-expressing KB1P-G3 cells targeted with the indicated sgRNAs. Cells were stained 3 hr after 10 Gy of
ionizing radiation (IR) for the indicated proteins. RAD51-positive cells are highlighted by the white arrowheads. The scale bar represents 5 mm.
(D–G) Quantification of confocal images, plotted as a box and whiskers plot. The box represents the 25th to 75th percentiles, and the whiskers show the
minimum tomaximumvalues. The experiment was performed at least twice, and data are plotted as a percentage of yH2AX- (D), 53BP1- (E), or RIF1-positive cells
(> 10 foci) (F) or RAD51-positive cells (> 5 foci) (G) per field. Statistics were performed by Kruskal-Wallis non-parametric test followed by Dunn’s multiple
comparisons test. The indicated cell lines were compared with sgNT-treated cells (****p < 0.0001).
See also Figure S3.Panier and Boulton, 2014). It was previously shown that the end
resection defect in BRCA1-deficient cells can be rescued via
loss of 53BP1, and this also rescued cell lethality induced by
BRCA1 loss (Bouwman et al., 2010; Bunting et al., 2012). Hence,
the finding that loss of the CST complex (Figure 3A) rescued
BRCA1 lethality points toward a potential inhibitory role in DSB
end resection. Moreover, depletion of CTC1 did not induce
PARPi resistance in BRCA2-deficient cells (Figures S2A and
S2B), which is in line with a possible role of the CST complex up-
stream of BRCA2.
DSB end resection produces ssDNA overhangs, which are
protected from nucleolytic degradation and the formation of sec-2112 Cell Reports 23, 2107–2118, May 15, 2018ondary structures by the coating of RPA. Therefore, we visual-
ized RPA loading in response to a-particle-induced DNA dam-
age by immunofluorescence as a readout for end resection
(Stap et al., 2008). In line with previous studies (Tka´c et al.,
2016; Xu et al., 2015), KB1P-G3 tumor cells showed a clear
resection defect that was partially restored in Ctc1-mutated
KB1P-G3 cells but not in sgNT-transfected control cells (Figures
4A and 4B).
We next investigated whether CTC1 loss affects the recruit-
ment of DDR factors to sites of irradiation-induced DNA dam-
age. CRISPR/SpCas9-targeted KB1P-G3 cells were either left
untreated or treated with 10 Gy of IR, which potently induced
yH2AX foci (Figures 4C and 4D; Figures S3A and S3B). Although
depletion of 53BP1 in KB1P-G3 cells abolished the formation of
IR-induced 53BP1 and RIF1 foci, these effects were not
observed in CTC1-depleted cells (Figures 4E and 4F and S3C
and S3D). Despite the capacity to form 53BP1 and RIF1 foci,
KB1P-G3 cells that were depleted of CTC1 restored IR-induced
RAD51 focus formation, whereas sgNT-transfected control cells
were deficient for this activity (Figures 4G and S3E). Similar con-
clusions were obtained when DNA damage was induced by
treatment with 500 nM olaparib for 24 hr (Figures S3A and
S3F–S3M). As expected, PARPi treatment resulted in more
heterogeneous DNA damage induction compared with IR
because PARP inhibition primarily exerts its cytotoxic effects
during replication.
We then tested whether CTC1 loss resulted in productive HR
events in conditional BRCA1-deficient R26CreERT2;Brca1SCo/D;
Pim1DR-GFP/wt mESC cells carrying a stably integrated DR-GFP
reporter (Bouwman et al., 2013). These cells were transfected
to transiently express mCherry and I-SceI, and the percentage
of mCherry/GFP double-positive cells was quantified by fluores-
cence-activated cell sorting (FACS) 24 hr later. Switching of the
conditional Brca1SCo allele impaired HR activity, which was
partially rescued upon depletion of the CST complex (Figures
S3N and S3O).
Together, these data support a role for CTC1 as a resection
antagonist acting on non-telomeric DSBs and as a mediator of
the HR defect in BRCA1-deficient cells.
CTC1 Facilitates c-NHEJ-Mediated Repair at Telomeric
and Non-Telomeric DSBs
It was previously shown that 53BP1, RIF1, and REV7/MAD2L2
antagonize resection and promote c-NHEJ (Boersma et al.,
2015; Bouwman et al., 2010; Bunting et al., 2010; Chapman
et al., 2013; Di Virgilio et al., 2013; Escribano-Dı´az et al., 2013;
Xu et al., 2015; Zimmermann et al., 2013). However, this is not
a universal phenotype for resection antagonists because it is
not shared by HELB (Tka´c et al., 2016). We therefore sought to
determine whether CTC1 affects NHEJ activity. First, we used
Terf2/;Trp53/ mouse embryonic fibroblasts (MEFs) that ex-
press a temperature-sensitive TRF2Ile468Ala mutant (TRF2ts) (Ko-
nishi and de Lange, 2008). TRF2ts is functional and maintains
intact TRF2-protected telomeres at 32C, but it dissociates
from telomeres at 37C–39C, inducing a DDR response and
end-to-end chromosome fusions (Konishi and de Lange, 2008).
It was previously demonstrated that these fusions are driven by
c-NHEJ and can be rescued by depletion of RNF8, DNA ligase
IV, or REV7/MAD2L2 (Boersma et al., 2015; Celli and de Lange,
2005; Peuscher and Jacobs, 2011; Smogorzewska et al., 2002).
We depleted CTC1 in TRF2ts MEFs grown under permissive
conditions (Figure 5A), which did not affect cell cycle distribution
(Figures S4A and S4B). Cells were then grown at the non-permis-
sive temperature (39C) for 24 h to uncap telomeres and induce
a DDR response prior to harvesting metaphase spreads for
telomere fluorescence in situ hybridization (FISH). Although
chromosome fusions were readily observed in control cells
upon temperature-induced TRF2 inactivation, this was signifi-
cantly reduced in Ctc1-mutated cells (Figures 5B and 5C; Fig-
ures S4C–S4E). In line with this finding and with NHEJ beinginhibited by long ssDNA overhangs, it was previously shown
that depletion of CTC1 increased ssG overhang length (Chen
et al., 2012; Gu et al., 2012).
We next assessed whether CTC1 depletion in mouse CH12 B
cells affects the ability to undergo class switch recombination
(CSR) as a measure for non-telomeric c-NHEJ capacity (Mura-
matsu et al., 2000). CH12 cells were transfected with Ctc1-tar-
geting CRISPR/SpCas9 constructs and subcloned to obtain
Ctc1-mutated CH12 cell clones. Notably, only 2 of 96 tested
clones showed heterozygous Ctc1 allele disruption, and no ho-
mozygous knockouts were obtained (Figures S4F and S4G),
raising the possibility that complete loss of CTC1 is lethal
in CH12 cells. Wild-type and heterozygous Ctc1 knockout
clones were subsequently stimulated with CD40Ab, inter-
leukin-4 (IL-4), and transforming growth factor b-1 (TGF-b-1,
CD40Ab, IL-4, and TGFb-1 [CIT]) to induce CSR from immuno-
globulin M (IgM) to IgA, which was monitored by flow cytometry.
Interestingly, heterozygous knockout of Ctc1 significantly dimin-
ished CSR in both clones (Figures 5D and 5E). We therefore
conclude that CTC1 facilitates DSB repair via c-NHEJ at both te-
lomeric and non-telomeric regions.
Depletion of CTC1 Mediates PARPi Resistance in the
KB1P Mouse Model
Last, we explored the in vivo effects of CTC1 on the treatment
response of BRCA1-deficient tumors to PARP inhibition. We
analyzed whether Ctc1 mRNA expression levels were altered
in our previously generated collection of BRCA1- and p53-defi-
cient KB1P and KB1PM mouse mammary tumors with acquired
resistance to PARP inhibition (Jaspers et al., 2013). In total, this
collection comprises 60 treatment-naive tumors and 85matched
PARPi-resistant tumors derived from 23 unique donors. To
examine the expression levels of Ctc1 in treatment-naive and
PARPi-resistant tumors, we produced RNA sequencing (RNA-
seq) data for all tumors (E.G., unpublished data) and obtained
the normalized expression values using edgeR (Robinson
et al., 2010). We observed that the expression of Ctc1 is signifi-
cantly downregulated in PARPi-resistant tumors compared with
naive tumors (p = 6.34 3 104) (Figure 6A). Moreover, in tumors
for which copy number variation by sequencing (CNVseq) data
were available, CTC1 mRNA downregulation correlated with
CNV loss (Figures S5A and S5D). Although a similar correlation
was observed for STN1 and TEN1, these factors were not signif-
icantly downregulated in resistant tumors (Figures S5B, S5C,
S5E, and S5F).
Finally, we usedmammary tumor organoid technology (Duarte
et al., 2018) to perform an in vivo intervention study with the
PARPi olaparib in mice carrying tumors derived from isogenic
KB1P organoids with or without disruption of Ctc1. For this pur-
pose, KB1P4 organoids, derived from a KB1P mammary tumor,
were cultured ex vivo and co-transduced with lentiviruses pro-
duced from pCMV-SpCas9 and pLenti-sgCtc1-tetR-T2A-Puro
vectors. Control organoids were generated by co-transduction
with pCMV-SpCas9 and pLenti-sgNT-tetR-T2A-Puro lentivirus
encoding a non-targeting sgRNA (Figure 6B). The transduced
KB1P4 tumor organoids were orthotopically transplanted in
mice that were left untreated or treated daily with the PARPi
olaparib for 56 consecutive days when tumors reached a sizeCell Reports 23, 2107–2118, May 15, 2018 2113
Figure 5. CTC1 Facilitates c-NHEJ at Telomeric and Non-telomeric DSBs
(A–C) CTC1 depletion suppresses end-to-end fusions of uncapped telomeres.
(A) Schematic overview of the telomere fusion assay. TRF2tsmouse embryonic fibroblasts (MEFs) of the indicated genotypes were cultured at the non-permissive
temperature (39C) for 24 hr before harvesting.
(B) Representative images of metaphase spreads showing chromosomes unfused or fused at their telomeres (examples highlighted by white arrowheads).
Chromosomes were stained with DAPI and a telomere-specific FISH probe (green).
(C) Metaphases were detected and imaged automatically by Metafer. At least two independent experiments were performed, in each independent experiment,
more than 2,000 chromosomeswere countedmanually. Genotypes were blinded during counting. Data are plotted asmean ±SEM. Significance was determined
by unpaired two-tailed Student’s t test (*p% 0.05; **p% 0.01).
(D and E) Heterozygous inactivation of Ctc1 impairs IgM-to-IgA class switch recombination (CSR) in CH12 B cells.
(D) FACS analysis of CH12 clones of the indicated genotype 40 hr after induction of CSR by incubation with CD40Ab, IL-4, and TGF-b-1 (CIT).
(E) Quantification of FACS data, representing mean ± SD of two independent experiments. Significance was calculated by unpaired Student’s t test
(**p value% 0.01).of 50–100 mm3. As expected, the Ctc1 target site was efficiently
disrupted in tumors derived from KB1P4 organoids transduced
with pCMV-SpCas9 and pLenti-sgCtc1-tetR-T2A-Puro (Figures
6C and 6D). Although KB1P4 control tumors only relapsed after
treatment was stopped, CTC1-depleted tumors relapsed during
treatment, resulting in accelerated mammary tumor-related
death (median latencies: 39 days for sgCtc1_2 and 42 days for
sgCtc1_3 cohorts compared with 73 days for control animals;
log rank test, p = 0.0019 and p = 0.0086, respectively; Figure 6E).
These data confirmed that depletion of CTC1 confers PARPi
resistance in BRCA1-deficient tumors in vivo.
DISCUSSION
In this study, we show that loss of the CST complex members
CTC1, STN1, and TEN1 induces PARPi resistance in tumors
with irreversible loss of function of BRCA1. Our data highlight2114 Cell Reports 23, 2107–2118, May 15, 2018the CST complex as a pathway for tumor cells to escape the syn-
thetic lethal effects of PARPi by restoring HR independently of
BRCA1. In particular, we demonstrate that the underlying mech-
anism is a restoration of end resection of DSBs. Together, our
findings demonstrate that the CST complex contributes to the
regulation of DNA end stability not only at telomeres but also
at non-telomeric DSBs.
We and others have recently shown that the 53BP1-RIF1-
REV7/MAD2L2 pathway is crucial for blocking end resection of
DSBs (Boersma et al., 2015; Bouwman et al., 2010; Bunting
et al., 2010; Chapman et al., 2013; Di Virgilio et al., 2013; Escri-
bano-Dı´az et al., 2013; Xu et al., 2015; Zimmermann et al.,
2013). However, it has remained elusive how DNA end stability
is regulated by 53BP1-RIF1-REV7/MAD2L2 because none of
these factors have been shown to contain direct DNA binding ca-
pacity and do not contain DNA processing activities. Our finding
that the CST complex functions as a resection antagonist at
Figure 6. Depletion of CTC1 Induces PARP Inhibitor Resistance In Vivo
(A) mRNA expression levels of Ctc1 in matched treatment-naive and PARPi-resistant BRCA1-deficient mouse mammary tumors. The y axis indicates the log2
(counts per million) value.
(B) Schematic overview of the generation of isogenic Ctc1-mutated and control tumors via ex vivo manipulation of tumor organoids.
(C and D) Example TIDE plots of untreated mammary tumors derived from Ctc1-mutated KB1P4 tumor organoids of the indicated genotype.
(E) Survival of mice orthotopically transplanted with modified KB1P4 tumor organoids. Mice were stratified into untreated (n = 3) or olaparib-treated (100 mg/kg
intraperitoneally daily for 56 consecutive days, n = 7) groups when tumors reached a size of 50–100 mm3. Significance was calculated by log rank (Mantel-Cox)
test (**p < 0.01).DSBs sheds light on this puzzle. The CST complex is an RPA-like
complex that can directly bind ssDNA via multiple OB folds
(Miyake et al., 2009). In collaboration with the laboratory of
Dan Durocher, we recently identified another RPA-like complex,
the Shieldin (SHLD) complex, which is composed of SHLD1
(C20ORF196), SHLD2 (FAM35A), SHLD3 (FLJ26957/CTC-
534A2.2), and REV7/MAD2L2, as a downstream effector of
53BP1 in DSB repair (unpublished data). Hence, in addition to
RPA and the SHLD complex, the CST complex is another trimeric
complex that contains direct DNA binding capacity and affects
DSB end stability. How these three complexes are recruited to
DSBs in time and space remains to be elucidated. Possibly,
RPA, SHLD, and CST compete for ssDNA at resected DSBs or
collapsed forks to either promote or antagonize HR. Not mutually
exclusive with this model, it is conceivable that these complexes
might contain specialized functions dependent on the ssDNA
substrate since the CST complex has been reported to preferen-
tially bind to and promotemelting of G-rich regions andG4-quad-
ruplexes (Bhattacharjee et al., 2017; Lue et al., 2013).
Future work is also required to elucidate whether these com-
plexes form the final step in the regulation of DSB end stability
(for instance, through steric hindrance) or whether additional
downstream factors are involved. Intriguingly, the CST complex
has been described to buffer resection at telomeres via POLA-
dependent fill-in DNA synthesis, which is required to prevent
excessive telomere erosion (Lazzerini-Denchi and Sfeir, 2016).
Our finding that the CST complex antagonizes resection at
non-telomeric DSBs raises the question of whether this is depen-
dent on POLA activity. Resection can possibly be antagonized
not only by shielding the ends of DSBs from end-processing ac-
tivities but also by directly counteracting ongoing resection viafill-in DNA synthesis. This buffering activity might fine-tune the
length of ssDNA around the DSB, which is vulnerable for nucle-
olytic degradation, and it might provide a rescue mechanism in
case HR cannot be completed.
The identification of the CST complex as a mediator of PARPi
response in BRCA1-deficient tumors might also have clinical im-
plications because loss-of-function mutations in the CST-en-
coding genes are predicted to cause clinical PARPi resistance.
Moreover, we expect that these alterations provide therapeutic
vulnerabilities because we recently found that depletion of the
53BP1-dependent DNA repair pathway enhances sensitivity to
IR (M.B., unpublished data).
EXPERIMENTAL PROCEDURES
Cell Culture and Gene Editing
The KB1P-G3 cell line was previously established from a K14cre;Brca1F/F;
Trp53F/F (KB1P) mouse mammary tumor and cultured as described by Jaspers
et al. (2013). The KB2P-3.4 cell line was previously established from a K14cre;
Brca2F/F;Trp53F/F (KB2P) mouse mammary tumor and cultured as described
by Evers et al. (2008). The KB1P4 3D tumor organoid line was previously estab-
lished from a Brca1/;p53/ mouse mammary tumor and cultured as
described byDuarte et al. (2018). Further in vitro culture details and gene editing
details are provided in the Supplemental Experimental Procedures.
Plasmids
Plasmids and cloning methods are provided in the Supplemental Experimental
Procedures.
PARPis
Olaparib (CAS 763113-22-0) and AZD2461 (CAS 1174043-16-3) were synthe-
sized by and purchased from Syncom (Groningen, the Netherlands). Talazo-
parib was purchased from Selleckchem (catalog no.S7048).Cell Reports 23, 2107–2118, May 15, 2018 2115
Genomic DNA Isolation, PCR Amplification, and TIDE Analysis
Allele modification frequencies were quantified from genomic DNA isolated
from tumor and cell line samples using Gentra Puregene (QIAGEN) according
to the manufacturer’s protocol. Target loci were amplified by PCR and submit-
ted for Sanger sequencing to confirm target modification using the TIDE
algorithm (Brinkman et al., 2014). Parental cells were used as a reference
sequence. PCR primer sequences are provided in Table S3. Further details
are provided in the Supplemental Experimental Procedures.
CRISPR Library Screens
Screening details are provided in the Supplemental Experimental Procedures.
Alpha Track Assay
Experiments were performed as described previously (Xu et al., 2015) with mi-
nor modifications. Details are provided in the Supplemental Experimental
Procedures.
Focus Formation Experiments
RAD51 immunofluorescence in CRISPR/SpCas9-transfected KB1P-G3 cells
was performed as described previously with minor modifications (Xu et al.,
2015). Details are provided in the Supplemental Experimental Procedures.
DR-GFP
The DR-GFP was performed as described previously (Bouwman et al., 2013).
Genes were targeted using the pLentiCRISPRv2 system containing the indi-
cated sgRNAs.
Assessment of Telomere NHEJ
Trf2/;Trp53/;TRF2ts (TRF2ts) MEFs were described before (Peuscher and
Jacobs, 2011), and metaphase chromosome analysis was done as described
before (Boersma et al., 2015). Details are provided in the Supplemental Exper-
imental Procedures.
CSR Assay
Immunoglobulin CSR was performed as described previously (Xu et al., 2015).
Details are provided in the Supplemental Experimental Procedures.
Generation of RNA-Seq Data
To determine the effects of Ctc1, Ten1, and Stn1 on PARPi treatment in vivo,
we used our RNA-seq dataset generated from a cohort of PARPi-naive
and -resistant KB1P and KB1PM tumors (Jaspers et al., 2013; E.G., unpub-
lished data). Further details are provided in the Supplemental Experimental
Procedures.
Generation of CNV Sequencing Data
Genomic DNA was isolated from a subset of matched naive-and resistant
KB1P-derived fresh-frozen tumor material using standard phenol:chloroform
extraction (Jaspers et al., 2013; E.G., unpublished data). Further details are
provided in the Supplemental Experimental Procedures.
In Vivo Studies
All animal experiments were approved by the Animal Ethics Committee of the
Netherlands Cancer Institute (Amsterdam, the Netherlands) and performed in
accordance with the Dutch Act on Animal Experimentation (November 2014).
Tumor organoids were allografted in 6- to 9-week-old female mice as
described previously (Duarte et al., 2018) withminor modifications. Further de-
tails are provided in the Supplemental Experimental Procedures.
Quantification and Statistical Analysis
Statistical differences were calculated in GraphPad Prism using Student’s
t tests. Statistical significance in Figure 2F was calculated by two-way
ANOVA and post hocDunnett’s correction formultiple comparisons and in Fig-
ure 2G by one-way ANOVA and post hoc Dunnett’s correction for multiple
comparisons. Statistical differences in Figures 4D–4G and Figures S3F–S3M
were calculated by Kruskal-Wallis non-parametric test and post hoc Dunnett’s
correction for multiple comparisons. Statistical differences in Figure 6E were
calculated by log rank Mantel-Cox test. Significance is as follows: p > 0.05,2116 Cell Reports 23, 2107–2118, May 15, 2018not significant (n.s.); *p% 0.05; **p% 0.01; ***p% 0.001; ****p% 0.0001 unless
otherwise stated in the figure legends. Original data files used to prepare the
figures in thismanuscript have been deposited inMendeley Data and are avail-
able at https://doi.org/10.17632/6wyzgw8z8k.1.
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be
directed to and will be fulfilled by S.R. (sven.rottenberg@vetsuisse.unibe.ch).
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw data of RNA-seq and CNV sequencing re-
ported in this paper is European Nucleotide Archive (ENA): PRJEB25803.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.04.046.
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